^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KJ-101

    i
    Other names: KJ-101
    Associations

    News

    Trials
    Company:
    KisoJi Biotech
    Drug class:
    PD1 inhibitor, CD47 inhibitor, DRD2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Pre-clinical development of a dopamine receptor 2, PD-1, and CD47 trispecific antibody for the treatment of solid tumors (AACR 2023)
    Conventional purification yields 99% purity and notably displays high stability under accelerated stability testing.In conclusion, the trispecific KJ-101 antibody has strong in vivo anti-tumor activity mediated via multiple mechanisms of action, is easily expressed and purified, and is very stable. Together, this data supports the clinical development of KJ-101 in advanced metastatic neuroendocrine cancer indications, including SCLC.
    Preclinical • PD(L)-1 Biomarker • IO biomarker • Trispecific
    |
    PD-1 (Programmed cell death 1) • CD34 (CD34 molecule) • DRD2 (Dopamine Receptor D2) • SIRPA (Signal Regulatory Protein Alpha)
    |
    DRD2 expression
    |
    KJ-101